51 results about "Lymphocyte antigen" patented technology

This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) another anti-cancer agent. The other anti-cancer agent can be a platinum-based doublet chemotherapy, an EGFR-targeted tyrosine kinase inhibitor, an anti-VEGF antibody, an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody, or any other therapy used to treat lung cancer in the art or disclosed herein.

Various embodiments of the invention provide binding molecules for B-lymphocyte antigen (e.g., CD 19 and CD20), including antigen recognizing receptors (e.g., CARs) that target B-lymphocyte antigens (e.g., CD 19 and CD20). Embodiments of the invention also provide cells expressing such binding molecules, therapeutics compositions comprising such cells, and methods for treating diseases or disorders associated with B-lymphocyte antigen (e.g., CD19 and CD20), including a hematologic cancer, an autoimmune disease (e.g., multiple sclerosis and systemic lupus erythematosus).

The invention provides a nano antibody targeting Ly6G6D and application of the nano antibody, particularly provides a nano antibody resisting Ly6G6D (a lymphocyte antigen 6 compound and a gene locus G61) and an antigen binding fragment, and further provides application of the nano antibody or the antigen binding fragment in preparation of drugs for treating Ly6G6D positive cancers.

The invention provides an antibody targeting Ly6G6D and application of the antibody, particularly provides an anti-Ly6G6D (lymphocyte antigen 6 complex and locus G61) antibody and an antibody fragment, and further provides application of the antibody or the antibody fragment in preparation of drugs for treating Ly6G6D positive cancers.

The invention discloses thymus dependent lymphocyte antigen epitope peptide of hepatitis B virus antigen and application, and belongs to the field of medical immunology and infectious pathology. The thymus dependent lymphocyte antigen epitope peptide of the hepatitis B virus antigen is characterized in that the amino acid sequence of the epitope peptide comprises any one or more of the following: SPTVWLSVI; an LPLLPIFFCL (low-performance liquid chromatography- CPTVQASKL, and CPTVQASKL; an LPSDFFPSI (Liquefied Peptide The amino acid sequence is an amino acid sequence obtained by removing or replacing a single amino acid of the amino acid sequence. The epitope peptide disclosed by the invention can be specifically combined with cytotoxic thymus dependent lymphocytes to stimulate the cytotoxic thymus dependent lymphocytes to activate, proliferate and differentiate, so that the immune effect of resisting the hepatitis B virus is exerted; the antigen peptides can be used for preparing therapeutic and prophylactic vaccines for hepatitis B virus infection, can also be used for preparing detection reagents for detecting hepatitis B virus specific cytotoxic thymus dependent lymphocytes, and have potential application value in prevention, treatment and diagnosis of hepatitis B.

Methods of treating colon cancer with antibodies that specifically bind to human cytotoxic T-lymphocyte antigen 4 (CTLA-4) are provided.

Provided are methods for treating colorectal cancer with an antibody that specifically binds to human Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4).

Immunoglobulin complementarity determining regions ("CDRs"), and immunoglobulin binding domains comprising those CDRs, that bind human lymphocyte antigen 6 family member G6D (LY6G6D), and their use for the preparation of LY6G6D-binding proteins finding use as immunotherapeutics.

Provided are methods for treating pancreatic cancer with an antibody that specifically binds to human Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4).

To provide a composition and method for targeted treatment of cancer such as blood cancer.SOLUTION: Disclosed are a CAR polypeptide including a target domain selectively binding to a B lymphocyte antigen (e.g., hematological malignant tumor, e.g., CD19, CD20, and / or CD22 antigen related to leukemia and / or lymphoma), and a chimeric antigen receptor (CAR) T-cell which expresses the polypeptide, and can be used together with an adoptive cell transfer. Also disclosed is a method for bringing antitumor immunity to a subject having blood cancer accompanied by adoptive transfer of a CAR T-cell.SELECTED DRAWING: None

A multi-specific antibody contains at least one binding site for a cell specific antigen and at least one binding site for a tumor-reactive lymphocyte antigen and a multi-specific antibody including an IgG antibody or fragment thereof that binds to a first antigen; and at least one scFv antibody that binds to a second antigen that is different from the first antigen and is linked to a C terminus of at least one light chain or heavy chain of said IgG antibody or fragment. The multi-specific antibody reversibly binds to at least one of the cell specific antigen and tumor-reactive lymphocyte antigen or the first antigen and the second antigen with a greater affinity at an aberrant condition than at a normal physiological condition. Conjugates of the multi-specific antibodies and methods for generating the multi-specific antibody are also provided.

Immunoglobulin complementarity determining regions (“CDRs”), and immunoglobulin binding domains comprising those CDRs, that bind human lymphocyte antigen 6 family member G6D (LY6G6D), and their use for the preparation of LY6G6D-binding proteins finding use as immunotherapeutics.

The present invention provides a means or the like capable of temporarily inhibiting expression of PD-1 or CTLA-4 protein. The present invention relates to an antisense oligonucleotide or the like capable of hybridizing with a nucleic acid sequence of an mRNA precursor and / or mature mRNA of Programmed Cell Death 1 (PD-1) protein or Cytotoxic T-lymphocyte Antigen-4 (CTLA-4) protein and suppressing or inhibiting the expression of PD-1 protein or CTLA-4 protein.

Various embodiments of the present application provide binding molecules for B-lymphocyte antigens (e.g., CD19 and CD20), including antigen recognizing receptors (e.g., CARs) that target B-lymphocyte antigens (e.g., CD19 and CD20). Embodiments of the present application also provide cells expressing such binding molecules, therapeutic compositions comprising such cells, and methods for treating diseases or disorders associated with B-lymphocyte antigens (e.g., CD19 and CD20), including hematological cancers, autoimmune diseases (e.g., multiple sclerosis and systemic lupus erythematosus).

To provide methods for treating cancer patients.SOLUTION: Provided is a pharmaceutical composition for administering to a cancer patient to treat a cancer patient, which comprises an immune checkpoint inhibitory antibody which blocks immune checkpoint, such as cytotoxicity T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1), the cancer is selected from the group consisting of colon cancer, stomach cancer, endometrial cancer, bile duct cancer, pancreatic cancer, and prostate cancer, and the cancer patient having a microsatellite instable cancer (MSI).SELECTED DRAWING: None

Immunoglobulin complementarity determining regions ("CDRs"), and immunoglobulin binding domains comprising those CDRs, that bind human lymphocyte antigen 6 family member G6D (LY6G6D), and their use for the preparation of LY6G6D-binding proteins finding use as immunotherapeutics.

Provided are an antibody targeting Ly6G6D and a use thereof. Specifically, provided are an anti-Ly6G6D (lymphocyte antigen 6 complex, locus G61) antibody and an antibody fragment. Further provided is a use of the antibody or antibody fragment in preparation of a drug for treating an Ly6G6D-positive cancer.

The present disclosure provides antibodies and polypeptides that specifically bind to lymphocyte antigen 6 family member K (LY6K). Also provided are compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

The present disclosure provides methods for treating a subject having lung cancer, the methods comprising administering to the subject a therapeutically effective amount of: (a) an antibody or antigen-binding portion thereof that specifically binds to the Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) an antibody or antigen-binding portion thereof that specifically binds to Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity.

To provide a composition for treating a subject suffering from lung cancer.SOLUTION: The composition comprises a combination of an antibody or antigen-binding portion thereof that specifically binds to the programmed cell death-1 (PD-1) receptor and inhibits PD-1 activity (an anti-PD-1 antibody or antigen-binding portion thereof) and an antibody or antigen-binding portion thereof that specifically binds to cytotoxic T-lymphocyte antigen-4 (CTLA-4) and inhibits CTLA-4 activity (an anti-CTLA-4 antibody or antigen-binding portion thereof) for use in treating a subject suffering from lung cancer, wherein the anti-PD-1 antibody, or antigen-binding portion thereof, is administered at a dose ranging from about 0.1 to 5.0 mg per kg of body weight approximately once every two weeks, and the anti-CTLA-4 antibody or antigen-binding portion thereof is administered at a dose ranging from about 1 to 5.0 mg per kg of body weight approximately once every 6 to 12 weeks.SELECTED DRAWING: None

Provided are an antibody targeting Ly6G6D and a use thereof. Specifically, provided are an anti-Ly6G6D (lymphocyte antigen 6 complex, locus G61) antibody and an antibody fragment. Further provided is a use of the antibody or antibody fragment in preparation of a drug for treating an Ly6G6D-positive cancer.

Methods of treating pancreatic cancer with antibodies that specifically bind to human cytotoxic T-lymphocyte antigen 4 (CTLA-4) are provided.

The present disclosure provides antibody-drug conjugates (ADCs) that specifically bind to lymphocyte antigen 6 family member K (LY6K). Also provided are compositions comprising these ADCs and methods of treating a subject using these ADCs.

The present disclosure provides antibodies and polypeptides that specifically bind to lymphocyte antigen 6 family member K (LY6K). Also provided are compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

The invention discloses an HLA-C restrictive SARS-CoV-2 lymphocyte antigen epitope peptide and application thereof, belongs to the fields of medical immunology and infectious pathology, and particularly relates to three thymus dependent lymphocyte antigen epitope peptides of SARS-CoV-2, the amino acid sequence of the epitope peptide is shown as any one of SEQ ID NO: 1-3, and the amino acid sequence of the epitope peptide is shown as any one of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6. Or an amino acid sequence obtained by substituting, deleting, inserting and / or adding one or more amino acid sequences in any sequence of SEQ ID NO: 1-3. The antigen epitope peptide can be presented by HLA-C0101 and HLA-C0602 molecules, and the activation, proliferation and differentiation of SARS-CoV-2 specific thymus dependent lymphocytes are stimulated, so that the immune effect of resisting SARS-CoV-2 infection is exerted; the antigen peptides can be used for preparing mixed polypeptide vaccines of SARS-CoV-2, recombinant protein vaccines connected with a plurality of epitope peptides in series and DNA and RNA vaccines, can be used for preparing a detection kit for detecting SARS-CoV-2 specific thymus dependent lymphocytes, and can also be used for preparing effector thymus dependent lymphocytes or drugs for treating SARS-CoV-2 infection. The SARS-CoV-2 antibody has a potential application value in the prevention, treatment and diagnosis of SARS-CoV-2 infection and COVID-19.

The present invention relates to isolated antibodies, fragments thereof and antibody-drug conjugates that bind to Lymphocyte antigen 6 family member K (LY6K) and their use for screening for LY6K-positive malignant cells or for therapeutic targeting of LY6K-positive malignant cells.

The present application belongs to the technical field of immunotherapy, and particularly relates to an antigen epitope peptide of lymphocyte antigen 6 complex site K and application thereof. The present application aims to provide a new method for treating or clinically detecting tumors with high expression of LY6K. The technical scheme of the present application is an antigen epitope peptide of lymphocyte antigen 6 complex site K, and the amino acid sequence is shown in SEQ ID No. 7. The present application provides an LY6K antigen epitope peptide, and the antigen epitope peptide can be used to prepare a pMHC complex or directly load an antigen presenting cell to activate T cells. Therefore, the antigen epitope peptide can be applied to the treatment or diagnosis of tumors with high expression of LY6K antigen.

Provided are methods for treating cancer with an antibody that specifically binds to human Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and an ectonucleotide pyrophosphatase / phosphodiesterase family member 1 (ENPP1) inhibitor.

The invention discloses an SARS-CoV-2 lymphocyte antigen epitope peptide and application thereof, belongs to the fields of medical immunology and infectious pathology, and particularly relates to three thymus dependent lymphocyte antigen epitope peptides of SARS-CoV-2. The epitope peptide is characterized in that the amino acid sequence of the epitope peptide is shown as any one of SEQ ID NO: 1-3; or an amino acid sequence obtained by substituting, deleting, inserting and / or adding one or more amino acid sequences in SEQ ID NO: 1-3. The antigen epitope peptide can be presented by HLA-DR molecules, and stimulates activation, proliferation and differentiation of SARS-CoV-2 specific thymus dependent lymphocytes, so that the immune effect of resisting SARS-CoV-2 infection is exerted; the antigen peptides can be used for preparing mixed polypeptide vaccines of SARS-CoV-2, recombinant protein vaccines connected with a plurality of epitope peptides in series and DNA and RNA vaccines, can be used for preparing a detection kit for detecting SARS-CoV-2 specific thymus dependent lymphocytes, and can also be used for preparing effector thymus dependent lymphocytes or drugs for treating SARS-CoV-2 infection. The SARS-CoV-2 antibody has a potential application value in the prevention, treatment and diagnosis of SARS-CoV-2 infection and COVID-19.

The invention belongs to the technical field of immunotherapy, and particularly relates to an antigen epitope peptide of a lymphocyte antigen 6 complex site K and application of the antigen epitope peptide. The technical problem to be solved by the invention is to provide a new method for tumor treatment or clinical detection of high-expression LY6K. The technical scheme of the invention is as follows: the amino acid sequence of the antigen epitope peptide of the lymphocyte antigen 6 complex site K is as shown in SEQ ID No.7. The invention provides an LY6K antigen epitope peptide. The antigen epitope peptide is used for preparing a pMHC compound or directly loaded antigen presenting cells, and T cells can be activated. Therefore, the epitope peptide can be applied to treatment or diagnosis of tumors with high expression of the LY6K antigen.